| Literature DB >> 32342760 |
Yuichiro Yano1, Yan Gao2, Dayna A Johnson3,4, Mercedes Carnethon5, Adolfo Correa6, Murray A Mittleman7,8, Mario Sims6, Elizabeth Mostofsky7,8, James G Wilson2, Susan Redline3,4.
Abstract
Background Characterizing associations of sleep characteristics with blood-glucose-level factors among blacks may clarify the underlying mechanisms of impaired glucose metabolism and help identify treatment targets to prevent diabetes mellitus in blacks. Methods and Results Cross-sectional analyses were conducted in 789 blacks who completed home sleep apnea testing and 7-day wrist actigraphy in 2012-2016. Sleep-disordered breathing measurements included respiratory event index associated with 4% oxygen desaturation and minimum oxygen saturation. Sleep patterns on actigraphy included fragmented sleep indices. Associations between sleep characteristics (8 exposures) and measures of glucose metabolism (3 outcomes) were determined using multivariable linear regression. Mean (SD) age of the participants was 63 (11) years; 581 (74%) were women; 198 (25%) were diabetes mellitus, and 158 (20%) were taking antihyperglycemic medication. After multivariable adjustment, including antihyperglycemic medication use, the betas (95% CI) for fasting glucose and hemoglobin A1c, respectively, for each SD higher level were 0.13 (0.02, 0.24) mmol/L and 1.11 (0.42, 1.79) mmol/mol for respiratory event index associated with 4% oxygen desaturation and 0.16 (0.05, 0.27) mmol/L and 0.77 (0.10, 1.43) mmol/mol for fragmented sleep indices. Among 589 participants without diabetes mellitus, the betas (95% CI) for homeostatic model assessment of insulin resistance for each SD higher level were 1.09 (1.03, 1.16) for respiratory event index associated with 4% oxygen desaturation, 0.90 (0.85, 0.96) for minimum oxygen saturation, and 1.07 (1.01, 1.13) for fragmented sleep indices. Conclusions Sleep-disordered breathing, overnight hypoxemia, and sleep fragmentation were associated with higher blood glucose levels among blacks.Entities:
Keywords: blacks; glucose metabolism; sleep
Year: 2020 PMID: 32342760 PMCID: PMC7428566 DOI: 10.1161/JAHA.119.013209
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Characteristics of JHS Sleep Study Participants (n=789)
| Characteristics | Mean±SD, Median±IQR, or Counts (Percentages) |
|---|---|
| Age, y, mean±SD | 63.1±10.7 |
| Women, n (%) | 518 (66) |
| Education, n (%) | |
| <High school | 77 (10) |
| High school or GED | 130 (16) |
| Some college/training or college degree | 582 (74) |
| BMI, kg/m2, mean±SD | 31.9±6.9 |
| Waist circumference, cm, mean±SD | 105.9±16.2 |
| Current smokers, n (%) | 65 (8) |
| Habitual drinkers, n (%) | 264 (34) |
| Fasting glucose, mmol/L, mean±SD | 6.0±1.8 |
| HOMA‐IR, median (IQR) | 2.7±2.4 |
| HbAlc, mmol/mol, mean±SD | 44.4±10.9 |
| Diabetes mellitus, n (%) | 212 (27) |
| Statin, n (%) | 241 (33) |
| Antihyperglycemic medication, n (%) | 158 (21) |
| Sleep‐disordered breathing measures | |
| REI4P (events/h), median (IQR) | 6.3±11.8 |
| REI3P (events/h), median (IQR) | 10.8±15.6 |
| Sat<90, %, median (IQR) | 0.35±2.20 |
| MinSaO2, %, median (IQR) | 86.0±8.0 |
| Sleep duration and continuity measures | |
| Sleep duration, h, mean±SD | 6.7±1.1 |
| Sleep maintenance efficiency, %, median (IQR) | 87.7 (5.9) |
| Sleep duration variability, min, mean±SD | 73.4±33.5 |
| Fragmented sleep indices, %, mean±SD | 29.3±8.8 |
Data are expressed as mean±SD, median (IQR), or counts (percentages). Sleep characteristic measures were obtained using polysomnography, and sleep habits were obtained using 7‐day actigraphy. BMI indicates body mass index; GED, general educational development; HbAlc, hemoglobin A1c; HOMA‐IR, homeostatic model assessment of insulin resistance; IQR, interquartile range; JHS, Jackson Heart Study; MinSaO2, minimum oxygen saturation; REI3P, apnea‐hypopnea index at 3% oxygen desaturation; REI4P, apnea‐hypopnea index at 4% oxygen desaturation; Sat<90, % sleep time with <90% oxyhemoglobin saturation.
Associations Between Sleep Disturbances and Measures of Glucose Metabolism, JHS Sleep Study, 2012–2016
| Fasting Glucose, mmol/L (n=789) | HbAlc, mmol/mol (n=772) | HOMA‐IR (n=576) | ||||
|---|---|---|---|---|---|---|
| Unadjusted | Adjusted | Unadjusted | Adjusted | Unadjusted | Adjusted | |
| Sleep‐disordered breathing measures | ||||||
| REI4P (events/h) | 0.22 (0.09, 0.34) | 0.13 (0.02, 0.24) | 1.54 (0.78, 2.30) | 1.11 (0.43, 1.78) | 1.17 (1.11, 1.24) | 1.09 (1.03, 1.16) |
| REI3P (events/h) | 0.23 (0.11, 0.35) | 0.13 (0.02, 0.25) | 1.60 (0.85, 2.36) | 1.11 (0.42, 1.79) | 1.19 (1.12, 1.26) | 1.11 (1.05, 1.18) |
| Sat<90, % | 0.13 (0.01, 0.26) | 0.07 (−0.03, 0.18) | 0.71 (−0.05, 1.47) | 0.28 (−0.36, 0.93) | 1.12 (1.05, 1.19) | 1.05 (0.99, 1.11) |
| MinSaO2, % | −0.19 (−0.31, −0.07) | −0.04 (−0.16, 0.07) | −1.39 (−2.16, −0.63) | −0.45 (−1.15, 0.25) | 0.82 (0.78, 0.87) | 0.90 (0.85, 0.96) |
| Sleep duration and continuity measures | ||||||
| Sleep duration, h | 0.10 (−0.03, 0.22) | 0.08 (−0.03, 0.19) | 0.08 (−0.70, 0.85) | −0.13 (−0.80, 0.53) | 0.98 (0.93, 1.04) | 1.02 (0.96, 1.08) |
| Sleep maintenance efficiency, % | −0.12 (−0.25, −0.00) | −0.14 (−0.25, −0.02) | −0.84 (−1.62, −0.06) | −0.67 (−1.37, 0.04) | 0.92 (0.87, 0.98) | 0.94 (0.89, 1.00) |
| Sleep duration variability, min | 0.20 (0.08, 0.33) | 0.21 (0.10, 0.31) | 0.87 (0.10, 1.64) | 0.72 (0.08, 1.37) | 1.02 (0.96, 1.08) | 0.99 (0.93, 1.04) |
| Fragmented sleep indices, % | 0.18 (0.06, 0.31) | 0.16 (0.05, 0.27) | 0.95 (0.18, 1.72) | 0.77 (0.10, 1.43) | 1.08 (1.01, 1.14) | 1.07 (1.01, 1.13) |
Sleep‐disordered breathing measures were obtained through home sleep apnea testing, and sleep duration and continuity measures were obtained using 7‐day actigraphy. β=standardized regression coefficient. Adjusted βs (95% CIs) associated with a 1‐SD increase in each sleep measure are shown. For HOMA‐IR, exponential βs were calculated, interpreted as a 1‐SD increase in each sleep measure would multiply the expected value of HOMA‐IR by exp(β). The 1‐SD increments for each sleep measure are as follows: REI4P, 13.68 events/h; REI3P, 15.89 events/h; Sat <90, 8.03%; MinSaO2, 6.37%; sleep duration, 1.13 h; sleep efficiency, 4.83%; sleep duration variability, 33.54 min; fragmented sleep indices, 8.75%. Each sleep measure was analyzed in a separate model. Regression coefficients and P values for each multiplicative interaction term are shown. Each sleep measure was analyzed in a separate model. Models include adjustment for age, sex, educational level, alcohol use, smoking status, BMI, antihyperglycemic medication use and prevalent diabetes mellitus, statin use, and sleep duration. Antihyperglycemic medication use and prevalent diabetes mellitus were not used in modeling for HOMA‐IR. Sleep duration was not used in modeling of sleep duration as an exposure. BMI indicates body mass index; HbAlc, hemoglobin A1c; HOMA‐IR, homeostatic model assessment of insulin resistance; JHS, Jackson Heart Study; MinSaO2, minimum oxygen saturation; REI3P, apnea‐hypopnea index at 3% oxygen desaturation; REI4P, apnea‐hypopnea index at 4% oxygen desaturation; Sat<90, % sleep time with <90% oxyhemoglobin saturation.
P<0.001.
P<0.05.
P<0.01.
Differences in Measures of Glucose Metabolism Across REI4P Subgroups: A Multiple Imputation Sample
| Fasting Glucose, mmol/L (n=789) | HbAlc, mmol/mol (n=772) | HOMA‐IR (n=576) | |
|---|---|---|---|
| Reference | Reference | Reference | |
| Unadjusted model REI4P <5 | |||
| 5 ≤REI4P <15 | 0.21 (−0.07, 0.49) | 0.86 (−0.90, 2.61) | 1.22 (1.07, 1.39) |
| 15 ≤REI4P <30 | 0.29 (−0.08, 0.66) | 1.79 (−0.50, 4.08) | 1.58 (1.33, 1.88) |
| REI4P ≥30 | 0.86 (0.41, 1.31) | 6.40 (3.63, 9.18) | 1.54 (1.24, 1.92) |
| Adjusted model REI4P <5 | |||
| 5 ≤REI4P <15 | 0.03 (−0.22, 0.28) | −0.09 (−1.61, 1.43) | 1.11 (0.99, 1.26) |
| 15 ≤REI4P <30 | 0.03 (−0.30, 0.36) | 0.20 (−1.77, 2.17) | 1.31 (1.11, 1.55) |
| REI4P ≥30 | 0.49 (0.08, 0.90) | 4.44 (2.02, 6.85) | 1.30 (1.05, 1.62) |
Differences in adjusted βs (95% CIs) associated with 5 ≤REI4P <15, 15 ≤REI4P <30, or REI4P ≥30 (vs REI4P <5) are shown. For HOMA‐IR, exponential βs were calculated, interpreted as a 1‐SD increase in each sleep measure would multiply the expected value of HOMA‐IR by exp(β). Of the 789 participants included in analyses for fasting glucose, 340 had REI4P <5, 263 had REI4P ≥5 and <15, 116 had REI4P ≥15 and <30, and 70 had REI4P ≥30. Of the 772 participants included in analyses for HbA1c, 330 had REI4P <5, 257 had REI4P ≥5 and <15, 115 had REI4P ≥15 and <30, and 70 had REI4P ≥30. Of the 589 participants included in analyses for HOMA‐IR, 266 had REI4P <5, 187 had REI4P ≥5 and <15, 79 had REI4P ≥15 and <30, and 44 had REI4P ≥30. Regression coefficients and P values for each multiplicative interaction term are shown. Each sleep measure was analyzed in a separate model. Models include adjustment for age, sex, educational level, alcohol use, smoking status, BMI, antihyperglycemic medication use and prevalent diabetes mellitus, statin use, and sleep duration. Antihyperglycemic medication use and prevalent diabetes mellitus were not used in modeling for HOMA‐IR. BMI indicates body mass index; HbAlc, hemoglobin A1c; HOMA‐IR, homeostatic model assessment of insulin resistance; REI3P, apnea‐hypopnea index at 3% oxygen desaturation; REI4P, apnea‐hypopnea index at 4% oxygen desaturation.
P<0.01.
P<0.001.
P<0.05.